Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative

Wataru Ito, Masaaki Toyama, Mika Okamoto, Masanori Ikeda, Koichi Watashi, Takaji Wakita, Yuichi Hashimoto, Masanori Baba

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The novel phenanthridinone derivative HA-719 has recently been identified as a highly potent and selective inhibitor of hepatitis C virus replication. To elucidate its mechanism of inhibition, we have isolated and analyzed a clone of hepatitis C virus replicon cells resistant to HA-719. Methods: To isolate HA-719-resistant replicon cells, Huh-7 cells containing subgenomic hepatitis C virus replicons (genotype 1b) with a luciferase reporter (LucNeo#2) were cultured in the presence of G418 and escalating concentrations of HA-719. After several passages, total RNA was extracted from the growing cells, and Huh-7 cells were transfected with the extracted RNA. Limiting dilution of the transfected cells was performed to obtain an HA-719-resistant clone. Results: The 50% effective concentration (EC50) of HA-719 for hepatitis C virus replication was 0.058 ± 0.012 µM in LucNeo#2 cells. The replicon cells capable of growing in the presence of G418 and 3 µM HA-719 were obtained after 18 passages (72 days). The HA-719-resistant clone LucNeo719R showed 98.3-fold resistant to the compound (EC50 = 5.66 ± 0.92 µM), but the clone had no cross-resistance to telaprevir (NS3 inhibitor), daclatasvir (NS5A inhibitor), and VX-222 (NS5B inhibitor). The sequence analysis for the wild-type and LucNeo719R identified 3, 2 and 7 mutations in NS3/4 A, NS4B, and NS5A, respectively, but no mutations in NS5B. Conclusion: None of the amino acid mutations in the resistant clone corresponds to those reported to confer drug-resistance to current anti-hepatitis C virus agents, suggesting that the target of HA-719 for hepatitis C virus inhibition differs from those of the existing agents.

Original languageEnglish
Pages (from-to)148-154
Number of pages7
JournalAntiviral Chemistry and Chemotherapy
Volume24
Issue number5-6
DOIs
Publication statusPublished - Dec 1 2015
Externally publishedYes

Fingerprint

Hepacivirus
Replicon
Clone Cells
Virus Replication
Mutation
RNA
4-butyl-11-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-7-methoxy-(1,3)dioxolo(4,5-c)phenanthridin-5(4H)-one
Luciferases
Drug Resistance
Sequence Analysis
Genotype
Amino Acids

Keywords

  • Drug resistance
  • hepatitis C virus
  • inhibitors

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology
  • Drug Discovery
  • Virology

Cite this

Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative. / Ito, Wataru; Toyama, Masaaki; Okamoto, Mika; Ikeda, Masanori; Watashi, Koichi; Wakita, Takaji; Hashimoto, Yuichi; Baba, Masanori.

In: Antiviral Chemistry and Chemotherapy, Vol. 24, No. 5-6, 01.12.2015, p. 148-154.

Research output: Contribution to journalArticle

Ito, W, Toyama, M, Okamoto, M, Ikeda, M, Watashi, K, Wakita, T, Hashimoto, Y & Baba, M 2015, 'Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative', Antiviral Chemistry and Chemotherapy, vol. 24, no. 5-6, pp. 148-154. https://doi.org/10.1177/2040206616663956
Ito, Wataru ; Toyama, Masaaki ; Okamoto, Mika ; Ikeda, Masanori ; Watashi, Koichi ; Wakita, Takaji ; Hashimoto, Yuichi ; Baba, Masanori. / Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative. In: Antiviral Chemistry and Chemotherapy. 2015 ; Vol. 24, No. 5-6. pp. 148-154.
@article{2bd5da6920804eb099f52b96fa82034b,
title = "Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative",
abstract = "Background: The novel phenanthridinone derivative HA-719 has recently been identified as a highly potent and selective inhibitor of hepatitis C virus replication. To elucidate its mechanism of inhibition, we have isolated and analyzed a clone of hepatitis C virus replicon cells resistant to HA-719. Methods: To isolate HA-719-resistant replicon cells, Huh-7 cells containing subgenomic hepatitis C virus replicons (genotype 1b) with a luciferase reporter (LucNeo#2) were cultured in the presence of G418 and escalating concentrations of HA-719. After several passages, total RNA was extracted from the growing cells, and Huh-7 cells were transfected with the extracted RNA. Limiting dilution of the transfected cells was performed to obtain an HA-719-resistant clone. Results: The 50{\%} effective concentration (EC50) of HA-719 for hepatitis C virus replication was 0.058 ± 0.012 µM in LucNeo#2 cells. The replicon cells capable of growing in the presence of G418 and 3 µM HA-719 were obtained after 18 passages (72 days). The HA-719-resistant clone LucNeo719R showed 98.3-fold resistant to the compound (EC50 = 5.66 ± 0.92 µM), but the clone had no cross-resistance to telaprevir (NS3 inhibitor), daclatasvir (NS5A inhibitor), and VX-222 (NS5B inhibitor). The sequence analysis for the wild-type and LucNeo719R identified 3, 2 and 7 mutations in NS3/4 A, NS4B, and NS5A, respectively, but no mutations in NS5B. Conclusion: None of the amino acid mutations in the resistant clone corresponds to those reported to confer drug-resistance to current anti-hepatitis C virus agents, suggesting that the target of HA-719 for hepatitis C virus inhibition differs from those of the existing agents.",
keywords = "Drug resistance, hepatitis C virus, inhibitors",
author = "Wataru Ito and Masaaki Toyama and Mika Okamoto and Masanori Ikeda and Koichi Watashi and Takaji Wakita and Yuichi Hashimoto and Masanori Baba",
year = "2015",
month = "12",
day = "1",
doi = "10.1177/2040206616663956",
language = "English",
volume = "24",
pages = "148--154",
journal = "Antiviral Chemistry and Chemotherapy",
issn = "0956-3202",
publisher = "International Medical Press Ltd",
number = "5-6",

}

TY - JOUR

T1 - Isolation and characterization of hepatitis C virus resistant to a novel phenanthridinone derivative

AU - Ito, Wataru

AU - Toyama, Masaaki

AU - Okamoto, Mika

AU - Ikeda, Masanori

AU - Watashi, Koichi

AU - Wakita, Takaji

AU - Hashimoto, Yuichi

AU - Baba, Masanori

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Background: The novel phenanthridinone derivative HA-719 has recently been identified as a highly potent and selective inhibitor of hepatitis C virus replication. To elucidate its mechanism of inhibition, we have isolated and analyzed a clone of hepatitis C virus replicon cells resistant to HA-719. Methods: To isolate HA-719-resistant replicon cells, Huh-7 cells containing subgenomic hepatitis C virus replicons (genotype 1b) with a luciferase reporter (LucNeo#2) were cultured in the presence of G418 and escalating concentrations of HA-719. After several passages, total RNA was extracted from the growing cells, and Huh-7 cells were transfected with the extracted RNA. Limiting dilution of the transfected cells was performed to obtain an HA-719-resistant clone. Results: The 50% effective concentration (EC50) of HA-719 for hepatitis C virus replication was 0.058 ± 0.012 µM in LucNeo#2 cells. The replicon cells capable of growing in the presence of G418 and 3 µM HA-719 were obtained after 18 passages (72 days). The HA-719-resistant clone LucNeo719R showed 98.3-fold resistant to the compound (EC50 = 5.66 ± 0.92 µM), but the clone had no cross-resistance to telaprevir (NS3 inhibitor), daclatasvir (NS5A inhibitor), and VX-222 (NS5B inhibitor). The sequence analysis for the wild-type and LucNeo719R identified 3, 2 and 7 mutations in NS3/4 A, NS4B, and NS5A, respectively, but no mutations in NS5B. Conclusion: None of the amino acid mutations in the resistant clone corresponds to those reported to confer drug-resistance to current anti-hepatitis C virus agents, suggesting that the target of HA-719 for hepatitis C virus inhibition differs from those of the existing agents.

AB - Background: The novel phenanthridinone derivative HA-719 has recently been identified as a highly potent and selective inhibitor of hepatitis C virus replication. To elucidate its mechanism of inhibition, we have isolated and analyzed a clone of hepatitis C virus replicon cells resistant to HA-719. Methods: To isolate HA-719-resistant replicon cells, Huh-7 cells containing subgenomic hepatitis C virus replicons (genotype 1b) with a luciferase reporter (LucNeo#2) were cultured in the presence of G418 and escalating concentrations of HA-719. After several passages, total RNA was extracted from the growing cells, and Huh-7 cells were transfected with the extracted RNA. Limiting dilution of the transfected cells was performed to obtain an HA-719-resistant clone. Results: The 50% effective concentration (EC50) of HA-719 for hepatitis C virus replication was 0.058 ± 0.012 µM in LucNeo#2 cells. The replicon cells capable of growing in the presence of G418 and 3 µM HA-719 were obtained after 18 passages (72 days). The HA-719-resistant clone LucNeo719R showed 98.3-fold resistant to the compound (EC50 = 5.66 ± 0.92 µM), but the clone had no cross-resistance to telaprevir (NS3 inhibitor), daclatasvir (NS5A inhibitor), and VX-222 (NS5B inhibitor). The sequence analysis for the wild-type and LucNeo719R identified 3, 2 and 7 mutations in NS3/4 A, NS4B, and NS5A, respectively, but no mutations in NS5B. Conclusion: None of the amino acid mutations in the resistant clone corresponds to those reported to confer drug-resistance to current anti-hepatitis C virus agents, suggesting that the target of HA-719 for hepatitis C virus inhibition differs from those of the existing agents.

KW - Drug resistance

KW - hepatitis C virus

KW - inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85007227362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007227362&partnerID=8YFLogxK

U2 - 10.1177/2040206616663956

DO - 10.1177/2040206616663956

M3 - Article

C2 - 27503576

AN - SCOPUS:85007227362

VL - 24

SP - 148

EP - 154

JO - Antiviral Chemistry and Chemotherapy

JF - Antiviral Chemistry and Chemotherapy

SN - 0956-3202

IS - 5-6

ER -